The capacity of IM to inhibit non-BCR/ABL1 targets has expanded its use to treatment of malignancies driven by KIT mutations, which has been implicated in CML pathogenesis. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.